PMID- 23909849
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20130805
IS  - 1528-1167 (Electronic)
IS  - 0013-9580 (Linking)
VI  - 54 Suppl 4
DP  - 2013 Aug
TI  - Development of new treatment approaches for epilepsy: unmet needs and 
      opportunities.
PG  - 3-12
LID - 10.1111/epi.12294 [doi]
AB  - A working group was created to address clinical "gaps to care" as well as 
      opportunities for development of new treatment approaches for epilepsy. The 
      working group primarily comprised clinicians, trialists, and pharmacologists. The 
      group identified a need for better animal models for both efficacy and 
      tolerability, and noted that animal models for potential disease-modifying or 
      antiepileptogenic effect should mirror conditions in human trials. For 
      antiseizure drugs (ASDs), current animal models have not been validated with 
      respect to their relationship to efficacy in common epilepsy syndromes. The group 
      performed an "expert opinion" survey of perceived efficacy of the available ASDs, 
      and identified a specific unmet need for ASDs to treat tonic-atonic and myoclonic 
      seizures. No correlation has as yet been demonstrated between animal models of 
      tolerability and adverse effects (AEs), versus tolerability in humans. There is a 
      clear opportunity for improved therapies in relation to dose-related AEs. The 
      group identified common and rare epilepsy syndromes that could represent 
      opportunities for clinical trials. They identified opportunities for 
      antiepileptogenic (AEG) therapies in both adults and children, acknowledging that 
      the presence of a biomarker would substantially improve the chances of a 
      successful trial. However, the group acknowledged that disease-modifying 
      therapies (given after the first seizure or after the development of epilepsy) 
      would be easier to study than AEG therapies.
CI  - Wiley Periodicals, Inc. (c) 2013 International League Against Epilepsy.
FAU - French, Jacqueline A
AU  - French JA
AD  - Department of Neurology, NYU School of Medicine, New York, New York 10016, USA. 
      Jacqueline.french@nyumc.org
FAU - White, H Steve
AU  - White HS
FAU - Klitgaard, Henrik
AU  - Klitgaard H
FAU - Holmes, Gregory L
AU  - Holmes GL
FAU - Privitera, Michael D
AU  - Privitera MD
FAU - Cole, Andrew J
AU  - Cole AJ
FAU - Quay, Ellinor
AU  - Quay E
FAU - Wiebe, Samuel
AU  - Wiebe S
FAU - Schmidt, Dieter
AU  - Schmidt D
FAU - Porter, Roger J
AU  - Porter RJ
FAU - Arzimanoglou, Alexis
AU  - Arzimanoglou A
FAU - Trinka, Eugen
AU  - Trinka E
FAU - Perucca, Emilio
AU  - Perucca E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Epilepsia
JT  - Epilepsia
JID - 2983306R
RN  - 0 (Anticonvulsants)
RN  - 0 (Drugs, Investigational)
SB  - IM
MH  - Animals
MH  - Anticonvulsants/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - *Drug Discovery
MH  - *Drug Evaluation, Preclinical
MH  - Drugs, Investigational/*therapeutic use
MH  - Epilepsies, Myoclonic/drug therapy
MH  - Epilepsy/*drug therapy
MH  - Epilepsy, Generalized/drug therapy
MH  - Epilepsy, Tonic-Clonic/drug therapy
MH  - *Health Services Needs and Demand
MH  - Humans
OTO - NOTNLM
OT  - Animal models
OT  - Antiepileptogenic therapy
OT  - Antiseizure therapy
OT  - Epilepsy syndromes
EDAT- 2013/08/09 06:00
MHDA- 2013/10/18 06:00
CRDT- 2013/08/06 06:00
PHST- 2013/08/06 06:00 [entrez]
PHST- 2013/08/09 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - 10.1111/epi.12294 [doi]
PST - ppublish
SO  - Epilepsia. 2013 Aug;54 Suppl 4:3-12. doi: 10.1111/epi.12294.